• Explore /
  • Poster
  • / Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.

Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.

Abstract Poster

Authors

null

Jean-Louis Legoux

Centre Hospitalier Régional, Orléans, France

Jean-Louis Legoux , Roger Faroux , Nicolas Barrière , Karine Le Malicot , David Tougeron , Veronique Lorgis , Veronique Guerin-Meyer , Vincent Bourgeois , David Malka , Thomas Aparicio , Mathieu Baconnier , Valérie Lebrun Ly , Joëlle Egreteau , Faïza Khemissa Akouz , Come Lepage , Valérie Boige

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

EudraCT 2014-001837-10

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3555)

DOI

10.1200/JCO.2022.40.16_suppl.3555

Abstract #

3555

Poster Bd #

349

Abstract Disclosures

Similar Posters

First Author: Atsushi Ishiguro

First Author: Zhichao Jiang

First Author: Hideaki Bando

First Author: Jaw-Yuan Wang